Welcome to our dedicated page for Embecta news (Ticker: EMBC), a resource for investors and traders seeking the latest updates and insights on Embecta stock.
Embecta Corp. (EMBC) generates a steady stream of news as a global diabetes care and medical supplies company listed on The Nasdaq Global Select Market. The company describes itself as advancing a 100-year legacy in insulin delivery and working to transform from an insulin delivery company into a broader medical supplies company. News about embecta often reflects this strategic evolution and its role in diabetes care worldwide.
Investors and observers can expect frequent updates tied to financial performance, including quarterly and full-year earnings results. embecta regularly issues press releases detailing revenues by geography and product family, operating margins, adjusted metrics, and guidance for upcoming fiscal years. These announcements are often accompanied by commentary on business drivers such as product volumes, pricing, foreign currency effects, and contract manufacturing activity.
Another key category of news covers strategic initiatives and partnerships. embecta has highlighted its global ERP implementation, brand transition from BD-branded to embecta-branded injection devices, and restructuring efforts aimed at improving profitability and reducing debt. The company also reports on collaborations with pharmaceutical partners to co-package embecta pen needles with potential generic GLP-1 therapies, as well as humanitarian partnerships, including large-scale donations of pen needles and insulin syringes through organizations such as Direct Relief.
embecta’s news flow also includes corporate governance and capital allocation topics, such as board changes, upcoming investor conferences, and regular announcements of quarterly cash dividends. Together, these updates provide insight into how embecta manages its diabetes-focused portfolio, pursues growth opportunities, and communicates with stockholders. For readers tracking EMBC, this news page offers an organized view of the company’s financial disclosures, strategic milestones, and corporate developments over time.
Embecta Corp. (Nasdaq: EMBC) reported its Q3 and 9-month fiscal 2022 results, revealing revenues of $291.1 million, a 1.3% decline year-over-year. In contrast, constant currency revenue increased by 2.0%. U.S. revenue grew by 4.1% while international revenue fell by 7.1%. Net income dropped to $62.4 million from $104.7 million in the previous year. Adjusted EBITDA was $117.9 million (40.5% margin), lower than last year. The company raised its second-half guidance for constant currency revenue growth and margins, while declaring a $0.15 quarterly dividend.
Embecta Corp. (NASDAQ: EMBC) has declared a quarterly cash dividend of $0.15 for each share of its common stock. This dividend will be paid on September 14, 2022 to stockholders of record as of August 26, 2022. As a leading pure-play diabetes care company, Embecta aims to support individuals with diabetes through innovative solutions, leveraging nearly a century of experience in insulin delivery.
Embecta Corp. (NASDAQ: EMBC) announced it will report its third-quarter financial results for fiscal year 2022 on August 15, 2022. The company’s management will hold a conference call at 8:00 a.m. ET to discuss results and provide an operational update. Embecta is positioned as a significant player in diabetes care following its spin-off from Becton, Dickinson and Company on April 1, 2022. The live webcast of the call will be accessible through the company’s investor relations website.
Embecta Corp. (Nasdaq: EMBC) reported Q2 2022 revenues of $274.5 million, a decline of 3.4% year-over-year. U.S. revenues dropped 5.8%, while international revenues saw a slight decrease of 0.8%. Net income was $79.6 million, down from $107.9 million in Q2 2021. Gross profit margin rose to 69.7%. For the first half of 2022, total revenue was $563.8 million, down 1.0%, with a net income of $178.4 million. The company anticipates a significant revenue decrease of about 7% for the second half of FY 2022, projecting revenues around $555 million due to continuing supply chain challenges.
Embecta Corp. (Nasdaq: EMBC) has announced its participation in two significant investor conferences. The 2022 RBC Capital Markets Global Healthcare Conference will feature a fireside chat on May 18 at 9:30 a.m. ET at the Intercontinental NY Barclay Hotel. Furthermore, the Piper Sandler Ophthalmology and Diabetes Symposium will include a virtual fireside chat on May 25 at 12:00 p.m. ET. Both presentations will be available for replay on the company’s investor relations website.
With nearly 100 years of experience in diabetes care, Embecta aims to empower diabetes patients worldwide.
Embecta Corp. (NASDAQ: EMBC) announced it will release its financial results for Q2 of fiscal 2022 on May 13, 2022, before market opening. A conference call is set for 8:00 AM ET to discuss the results, provide business updates, and share financial guidance for 2022. Participants can join via phone or a live webcast on the company's investor website. An audio replay will be available post-call. Embecta, focused on diabetes care, leverages a century of insulin delivery experience to support individuals with diabetes.
Embecta Corp. has launched as a leading global diabetes care company, with a history stretching back to 1924. As the largest producer of diabetes injection devices, Embecta manufactures around 8 billion devices annually, serving approximately 30 million patients worldwide. The company estimates the insulin delivery market to be valued at $6 billion to $8 billion per year. With operations spanning over 100 countries and a dedicated workforce of 2,000, Embecta aims to enhance shareholder value through strategic independence and innovation in diabetes care.